The SMN ELISA kit will enable and expedite drug discovery, development and therapy for Spinal Muscular Atrophy, a genetic cause of mortality in infants and toddlers.
The SMN ELISA Kit offers a reliable measure of SMN protein levels, and accelerates efficacy assessment of potential drugs in clinical trials that are designed to increase SMN protein levels.
The assay has been validated for use with human and mouse cell lysates and tissue homogenates, and will be marketed through Enzo’s worldwide sales and marketing group.